Ignite Creation Date:
2025-12-24 @ 11:55 PM
Ignite Modification Date:
2026-01-25 @ 11:59 PM
Study NCT ID:
NCT02849951
Status:
TERMINATED
Last Update Posted:
2017-06-15
First Post:
2016-07-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003093', 'term': 'Colitis, Ulcerative'}, {'id': 'D003092', 'term': 'Colitis'}, {'id': 'D014456', 'term': 'Ulcer'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D015212', 'term': 'Inflammatory Bowel Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}], 'ancestors': [{'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 25}}, 'statusModule': {'whyStopped': 'LT-02 did not appear to help induce remission of UC', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2016-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-06', 'completionDateStruct': {'date': '2019-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-06-13', 'studyFirstSubmitDate': '2016-07-26', 'studyFirstSubmitQcDate': '2016-07-26', 'lastUpdatePostDateStruct': {'date': '2017-06-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-07-29', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2019-03', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of clinical remission', 'timeFrame': '12 weeks', 'description': 'The percentage of subjects in clinical remission using the abbreviated modified Mayo score'}], 'secondaryOutcomes': [{'measure': 'Clinical response', 'timeFrame': '12 weeks', 'description': 'Percentage of subjects with clinical response using the abbreviated modified Mayo score'}, {'measure': 'Endoscopic response', 'timeFrame': '12 weeks', 'description': 'Percentage of subjects with endoscopic response'}, {'measure': 'Histological improvement', 'timeFrame': '12 weeks', 'description': 'Percentage of subjects with histological improvement'}, {'measure': 'Endoscopic remission', 'timeFrame': '12 weeks', 'description': 'Percentage of subjects with endoscopic remission'}, {'measure': 'Mucosal healing', 'timeFrame': '12 weeks', 'description': 'Percentage of subjects with mucosal healing'}, {'measure': 'Quality of life', 'timeFrame': '12 weeks', 'description': 'Change in the subjects quality of life, using Inflammatory Bowel Disease Quality of Life Questionnaire (IBDQ)'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Colitis', 'Colitis, Ulcerative', 'Ulcer', 'Colonic Diseases', 'Digestive System Diseases', 'Gastroenteritis', 'Gastrointestinal Diseases', 'Inflammatory Bowel Diseases', 'Intestinal Diseases', 'Pathologic Processes', 'Mesalamine'], 'conditions': ['Ulcerative Colitis']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine', 'detailedDescription': 'A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LT-02 (delayed release phosphatidylcholine granules; administered orally via 1.6 g BID for up to 12 weeks) in subjects with active ulcerative colitis who are refractory to a standard dose of oral mesalamine therapy. Refractory to mesalamine is defined as active disease despite receiving at least ≥ 2.4g mesalamine (or equivalent dose) for at least 8 weeks with or without rectal 5-ASA.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\n1. Established diagnosis of ulcerative colitis (UC), based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.\n2. Active UC with disease confirmed by endoscopy findings and confirmed by central reader.\n3. A modified Mayo Score 4-10, and with a centrally read endoscopy score activity of ≥ 2 points.\n4. Mesalamine (5-ASA) refractory.\n\nExclusion Criteria:\n\n1. Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), diverticular disease associated colitis,\n2. Toxic megacolon or fulminant colitis,\n3. Prior colon resection,\n4. Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile infection) at screening,\n5. Known celiac disease\n6. Other inflammatory or bleeding disorders of the colon and intestine, or diseases what may cause diarrhea or gastrointestinal bleeding\n7. History or presence of ischemic heart disease, myocardial infarction, peripheral arterial disease, ischemic stroke, or transient ischemic attack,\n8. Subjects with known hypersensitivity to soy,\n9. Treatment with methotrexate, azathioprine, 6-mercaptopurine TNF-alpha-antagonists, vedolizumab or certolizumab pegol, tacrolimus, or anti-integrin therapy within last 8 weeks prior to screening,\n10. Treatment with any (topical or systemic) corticosteroid formulation for the treatment of IBD within last 7 days prior to endoscopy,\n11. Treatment with other investigational drug within last 8 weeks prior to screening,"}, 'identificationModule': {'nctId': 'NCT02849951', 'acronym': 'PROTECT-3', 'briefTitle': 'A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Prometheus Laboratories'}, 'officialTitle': 'A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine', 'orgStudyIdInfo': {'id': '16GI01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'LT-02', 'description': '1.6 g PC in LT-02 BID', 'interventionNames': ['Drug: LT-02']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'LT-02 Placebo', 'description': '0 g PC in LT-02 Placebo BID', 'interventionNames': ['Drug: LT-02 Placebo']}], 'interventions': [{'name': 'LT-02', 'type': 'DRUG', 'description': '12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)', 'armGroupLabels': ['LT-02']}, {'name': 'LT-02 Placebo', 'type': 'DRUG', 'description': '12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo', 'armGroupLabels': ['LT-02 Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85018', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'Prometheus Site 24', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Prometheus Site 10', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '91910', 'city': 'Chula Vista', 'state': 'California', 'country': 'United States', 'facility': 'Prometheus Site 15', 'geoPoint': {'lat': 32.64005, 'lon': -117.0842}}, {'zip': '93534', 'city': 'Lancaster', 'state': 'California', 'country': 'United States', 'facility': 'Prometheus Site 42', 'geoPoint': {'lat': 34.69804, 'lon': -118.13674}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'country': 'United States', 'facility': 'Prometheus Site 30', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '92377', 'city': 'Rialto', 'state': 'California', 'country': 'United States', 'facility': 'Prometheus Site 28', 'geoPoint': {'lat': 34.1064, 'lon': -117.37032}}, {'zip': '93003', 'city': 'Ventura', 'state': 'California', 'country': 'United States', 'facility': 'Prometheus Site 2', 'geoPoint': {'lat': 34.27834, 'lon': -119.29317}}, {'zip': '80026', 'city': 'Lafayette', 'state': 'Colorado', 'country': 'United States', 'facility': 'Prometheus Site 27', 'geoPoint': {'lat': 39.9936, 'lon': -105.08971}}, {'zip': '80124', 'city': 'Lone Tree', 'state': 'Colorado', 'country': 'United States', 'facility': 'Prometheus Site 45', 'geoPoint': {'lat': 39.55171, 'lon': -104.8863}}, {'zip': '33756', 'city': 'Clearwater', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 35', 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'zip': '33319', 'city': 'Fort Lauderdale', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 17', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'zip': '33016', 'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 55', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'zip': '34102', 'city': 'Naples', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 8', 'geoPoint': {'lat': 26.14234, 'lon': -81.79596}}, {'zip': '34110', 'city': 'Naples', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 13', 'geoPoint': {'lat': 26.14234, 'lon': -81.79596}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 36', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '32807', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Prometheus Site 44', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '30607', 'city': 'Athens', 'state': 'Georgia', 'country': 'United States', 'facility': 'Prometheus Site 37', 'geoPoint': {'lat': 33.96095, 'lon': -83.37794}}, {'zip': '30033', 'city': 'Decatur', 'state': 'Georgia', 'country': 'United States', 'facility': 'Prometheus Site 11', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'zip': '60624', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Prometheus Site 53', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60169', 'city': 'Hoffman Estates', 'state': 'Illinois', 'country': 'United States', 'facility': 'Prometheus Site 54', 'geoPoint': {'lat': 42.04281, 'lon': -88.0798}}, {'zip': '66606', 'city': 'Topeka', 'state': 'Kansas', 'country': 'United States', 'facility': 'Prometheus Site 20', 'geoPoint': {'lat': 39.04833, 'lon': -95.67804}}, {'zip': '71105', 'city': 'Shreveport', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Prometheus Site 4', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'zip': '20815', 'city': 'Chevy Chase', 'state': 'Maryland', 'country': 'United States', 'facility': 'Prometheus Site 5', 'geoPoint': {'lat': 39.00287, 'lon': -77.07115}}, {'zip': '02379', 'city': 'Brockton', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Prometheus Research Site 1', 'geoPoint': {'lat': 42.08343, 'lon': -71.01838}}, {'zip': '48047', 'city': 'Chesterfield', 'state': 'Michigan', 'country': 'United States', 'facility': 'Prometheus Site 6', 'geoPoint': {'lat': 42.66281, 'lon': -82.84242}}, {'zip': '48034', 'city': 'Southfield', 'state': 'Michigan', 'country': 'United States', 'facility': 'Prometheus Site 51', 'geoPoint': {'lat': 42.47337, 'lon': -83.22187}}, {'zip': '49519', 'city': 'Wyoming', 'state': 'Michigan', 'country': 'United States', 'facility': 'Prometheus Site 48', 'geoPoint': {'lat': 42.91336, 'lon': -85.70531}}, {'zip': '55446', 'city': 'Plymouth', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Prometheus Site 31', 'geoPoint': {'lat': 45.01052, 'lon': -93.45551}}, {'zip': '63128', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Prometheus Site 40', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '03756', 'city': 'Lebanon', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'Prometheus Site 21', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'zip': '11021', 'city': 'Great Neck', 'state': 'New York', 'country': 'United States', 'facility': 'Prometheus Site 22', 'geoPoint': {'lat': 40.80066, 'lon': -73.72846}}, {'zip': '12601', 'city': 'Poughkeepsie', 'state': 'New York', 'country': 'United States', 'facility': 'Prometheus Site 33', 'geoPoint': {'lat': 41.70037, 'lon': -73.92097}}, {'zip': '10467', 'city': 'The Bronx', 'state': 'New York', 'country': 'United States', 'facility': 'Prometheus Site 26', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '27834', 'city': 'Greenville', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Prometheus Site 41', 'geoPoint': {'lat': 35.61266, 'lon': -77.36635}}, {'zip': '28501', 'city': 'Kinston', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Prometheus Site 32', 'geoPoint': {'lat': 35.26266, 'lon': -77.58164}}, {'zip': '29203', 'city': 'Columbia', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Prometheus Site 43', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'zip': '57701', 'city': 'Rapid City', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Prometheus Site 7', 'geoPoint': {'lat': 44.08054, 'lon': -103.23101}}, {'zip': '77090', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Prometheus Site 49', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77338', 'city': 'Humble', 'state': 'Texas', 'country': 'United States', 'facility': 'Prometheus Site 39', 'geoPoint': {'lat': 29.99883, 'lon': -95.26216}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Prometheus Site 47', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Prometheus Site 9', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '84058', 'city': 'Orem', 'state': 'Utah', 'country': 'United States', 'facility': 'Prometheus Site 23', 'geoPoint': {'lat': 40.2969, 'lon': -111.69465}}, {'zip': '84107', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Prometheus Site 25', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '22911', 'city': 'Charlottesville', 'state': 'Virginia', 'country': 'United States', 'facility': 'Prometheus Site 34', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'zip': '99352', 'city': 'Richland', 'state': 'Washington', 'country': 'United States', 'facility': 'Prometheus Site 12', 'geoPoint': {'lat': 46.28569, 'lon': -119.28446}}], 'overallOfficials': [{'name': 'Gregory Gordon, M.D., J.D.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Nestle Health Science, Medical Director'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Prometheus Laboratories', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Nestlé Health Science Spain', 'class': 'INDUSTRY'}, {'name': 'Syneos Health', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}